U.S. court denies Jazz Pharma bid to revive patents on narcolepsy drug

VAM Funds names Robert Gordon director of two funds

[ccpw id=”6606″]

July 13 (Reuters) – A U.S. appeals court on Friday ruled invalid patents owned by Jazz Pharmaceuticals PLC covering its narcolepsy drug Xyrem, opening the door for Amneal Pharmaceuticals Inc to launch a generic version of the medicine.

The U.S. Court of Appeals for the Federal Circuit affirmed a series of rulings in favor of Amneal that the Jazz patents described obvious ideas.

Reporting by Jan Wolfe
Editing by Chizu Nomiyama

Original Source